Contingent non-invasive prenatal testing: An opportunity to improve non-genetic aspects of fetal aneuploidy screening

Prenatal Diagnosis

Volumn 35, Issue 13, 2015, Pages 1347-1352

  Gyselaers, Wilfried ^a,b   Hulstaert, Frank ^c   Neyt, Mattias ^c  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; ARTICLE; BELGIUM; CONTINGENT VALUATION; COST BENEFIT ANALYSIS; DOWN SYNDROME; ECONOMIC ASPECT; HEALTH INSURANCE; LIVE BIRTH; PRENATAL SCREENING; PRIORITY JOURNAL; SIMULATION; ECONOMIC MODEL; ECONOMICS; FEMALE; HUMAN; MASS SCREENING; PREGNANCY; PRENATAL DIAGNOSIS;

ANEUPLOIDY; FEMALE; HUMANS; MASS SCREENING; MODELS, ECONOMIC; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84954399913     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4704     Document Type: Article

References (33)

1. Hui L, Teoh M, da Silva Costa F, et al. Clinical implementation of cell-free DNA based aneuploidy screening: perspectives from a national audit. Ultrasound Obstet Gynecol 2014, DOI: 10.1002/uog.14699 [Epub ahead of print].
2. Kagan KO, Eiben B, Kozlowski P. Combined first trimester screening and cell-free fetal DNA-"next generation screening". Ultraschall Med 2014;35:229-36.
3. Kagan KO, Wright D, Nicolaides KH. First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2014, DOI: 10.1002/uog.14691 [Epub ahead of print].
4. Nicolaides K, Syngelaki A, Poon L, et al. First trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing. Fetal Diagn Ther 2014;35:185-92.
5. Petersen OB, Vogel I, Ekelund C, et al. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol 2014;43:265-71.
6. Gyselaers WJ, Vereecken AJ, Van Herck EJ, et al. Screening for trisomy 21 in Flanders: a 10years review of 40.490 pregnancies screened by maternal serum. Eur J Obstet Gynecol Reprod Biol 2004;115:185-9.
7. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191:45-67.
8. Gyselaers WJ, Vereecken AJ, Van Herck EJ, et al. Audit on nuchal translucency thickness measurements in Flanders, Belgium: a plea for methodological standardization. Ultrasound Obstet Gynecol 2004;24:511-5.
9. Cammu H, Martens G, De Coen K, et al. Perinatal Activities in Flanders 2005. Studycentre for Perinatal Epidemiology (SPE): Brussels; 2006.
10. Khoshnood B, Greenlees R, Loane M, et al. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Res A Clin Mol Teratol 2011;91(Suppl 1):S16-22.
11. Cammu H, Martens E, Van Mol C, Jacquemyn Y. Perinatal Activities in Flanders 2012. Studycentre for Perinatal Epidemiology (SPE): Brussels; 2013.
12. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33:622-9.
13. Morris S, Karlsen S, Chung N, et al. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free DNA in the UK national health service. PLoS One 2014;9(4):e93559, DOI: 10.1371/journal.pone.0093559.
14. Hulstaert F, Neyt M, Gyselaers W. The non-invasive prenatal test (NIPT) for trisomy 21-health economic aspects. Belgian Health Care Knowledge Centre (KCE): Brussels; 2014.
15. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open 2014;4(11):e005922, DOI: 10.1136/bmjopen-2014-005922.
16. Cleemput I, Neyt M, Van de Sande S, et al. Belgian Guidelines for Economic Evaluations and Budget Impact Analyses, 2nd ed. Belgian Health Care Knowledge Centre(KCE): Brussels; 2012.
17. Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2-6.
18. Richter J, Henry A, Ryan G, et al. Amniopatch procedure after previable iatrogenic rupture of the membranes: a two-center review. Prenat Diagn 2013;33:391-6.
19. Saucedo MC, DeVigan C, Vodovar V, et al. Measurement of nuchal translucency and the prenatal diagnosis of Down syndrome. Obstet Gynecol 2009;114:829-38.
20. Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14weeks of gestation. Lancet 1998;352:343-6.
21. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 2013;42:15-33.
22. Gyselaers WJ, Vereecken AJ, Van Herck EJ, et al. Population screening for fetal trisomy 21: easy access to screening should be balanced against a uniform ultrasound protocol. Prenat Diagn 2005;25:984-90.
23. Nicolaides KH, Wright D, Poon LC, et al. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013;42:41-50.
24. Loane M, Morris JK, Addor MC, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 2013;21:27-33.
25. Wu J, Morris JK. Trends in maternal age distribution and the live birth prevalence of Down's syndrome in England and Wales: 1938-2010. Eur J Hum Genet 2013;21:943-7.
26. van Gameren-Oosterom HB, Buitendijk SE, Bilardo CM, et al. Unchanged prevalence of Down syndrome in the Netherlands: results from an 11-year nationwide birth cohort. Prenat Diagn 2012;32:1035-40.
27. Lo JO, Cori DF, Norton ME, et al. Noninvasive prenatal testing. Obstet Gynecol Surv 2014;69:89-99.
28. Lau TK, Cheung SW, Lo PS, et al. Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. Ultrasound Obstet Gynecol 2014;43:254-64.
29. Gekas J, Langlois S, Ravitsky V, et al. Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma. Appl Clin Genet 2014;7:127-31.
30. Bromley B, Shipp TD, Lyons J, et al. Detection of fetal structural anomalies in a basic first-trimester screening program for aneuploidy. J Ultrasound Med 2014;33:1737-45.
31. Quezada MS, Gil MD, Francisco C, et al. Screening for trisomies 21, 18 and 13 cell-free DNA analysis of maternal blood at 10-11weeks' gestation and the combined test at 11-13weeks. Ultrasound Obstet Gynecol 2014, DOI: 10.1002/uog.14664. [Epub ahead of print]
32. Ayres AC, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol 2014;54:412-7.
33. Salomon LJ, Alfirevic Z, Audibert F, et al. ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound Obstet Gynecol 2014;44:122-3.